
Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Stock analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Janux Therapeutics in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($1.48) for the year, up from their previous estimate of ($1.69). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q4 2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.45) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.57) EPS, FY2027 earnings at ($1.92) EPS, FY2028 earnings at ($2.75) EPS, FY2029 earnings at ($3.06) EPS and FY2030 earnings at ($2.04) EPS.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13. The firm had revenue of $9.29 million for the quarter, compared to analysts’ expectations of $8.03 million.
Other research analysts also recently issued research reports about the stock. Truist Financial lifted their price target on shares of Janux Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Citigroup reissued a “buy” rating on shares of Janux Therapeutics in a research report on Thursday, November 12th. Wolfe Research lowered shares of Janux Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Thursday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Friday, October 16th. Finally, Wedbush lifted their price objective on shares of Janux Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.92.
Get Our Latest Stock Analysis on JANX
Janux Therapeutics Stock Down 1.9%
Shares of NASDAQ:JANX opened at $10.71 on Monday. The firm’s 50 day moving average price is $16.43 and its 200 day moving average price is $15.32. The stock has a market cap of $655.24 million, a price-to-earnings ratio of -6.74 and a beta of 2.44. Janux Therapeutics has a fifty-two week low of $10.50 and a fifty-two week high of $35.34.
Institutional Investors Weigh In On Janux Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of JANX. BlackRock Inc. purchased a new position in Janux Therapeutics during the 2nd quarter worth approximately $94,228,000. State Street Corp increased its position in Janux Therapeutics by 22.0% during the second quarter. State Street Corp now owns 3,004,899 shares of the company’s stock worth $46,155,000 after buying an additional 540,882 shares during the period. Alyeska Investment Group L.P. increased its position in Janux Therapeutics by 2.9% during the second quarter. Alyeska Investment Group L.P. now owns 1,647,140 shares of the company’s stock worth $25,300,000 after buying an additional 46,051 shares during the period. Goldman Sachs Group Inc. lifted its stake in Janux Therapeutics by 7.8% in the third quarter. Goldman Sachs Group Inc. now owns 1,027,073 shares of the company’s stock valued at $17,748,000 after buying an additional 74,398 shares during the last quarter. Finally, Algert Global LLC lifted its stake in Janux Therapeutics by 150.5% in the second quarter. Algert Global LLC now owns 1,110,889 shares of the company’s stock valued at $17,063,000 after buying an additional 667,492 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.
Janux Therapeutics Company Profile
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors. Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.
Recommended Stories
- Five stocks we like better than Janux Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
